A variety of other immunohistochemical markers, such as Ki-67 p53, VEGF, EGFR, CD10; flow cytometry analysis of ploidy and S-phase, cytogenetic studies and quantitative measures of stromal cellularity, stromal-to-epithelial ratio, mitotic rate, stromal overgrowth, and mean nuclear diameter were studied, in order to distinguish cellular fibroadenomas from benign phyllodes tumors and subclassify benign, borderline, and malignant phyllodes tumors. The gene discussed is MME; the disease is malignant breast phyllodes tumor.